COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.

All attention now turns to the ongoing dialogue with the U.S. Food and Drug Administration (FDA). Compass Pathways is pursuing an accelerated review pathway, with the goal of submitting a formal New ...

Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings Conference Call. Please note that this call is being recorded. COMPASS Pathways plc (NASDAQ:CMPS) is among the ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Ladies and gentleman thank you for standing by, and welcome to the COMPASS Pathways' Ltd. Fourth Quarter 2024 Investor Call. [Operator Instructions] I would now hand today’s call over to Steve Schultz ...

COMPASS Pathways PLC ADR stock grades by Barron's. View CMPS fundamental and sentiment analysis powered by MarketGrader.